The telehealth MOM study: Protocol for a randomized controlled trial of the telehealth multi-component optimal model (MOM) of postpartum care
Abstract
OBJECTIVES
This cross-sectional study of hospital emergency departments (EDs) in Arkansas sought to: 1) assess ED experiences and capabilities related to obstetric emergencies, and; 2) characterize the differences in ED practices for pregnant and postpartum patients between hospitals with and without obstetric services.
METHODS
Online survey invitations were distributed to department managers at hospital EDs across Arkansas in August 2023. The 40-question survey collected hospital characteristics, ED experiences with and capacity to manage obstetric emergencies, and staff training history and interest. Responses were descriptively analyzed, and differences in proportions between hospitals with and without obstetric services were tested.
RESULTS
Managers for 51 (61 %) of the 84 eligible EDs responded. Seventy-one percent of EDs (35/49) had an urgent transport of a pregnant or postpartum patient, and 43 % (20/47) had a birth in the prior 12 months. EDs in hospitals without obstetric services were less likely to have a birth (27 % v. 56 %), to have capacity to perform some obstetric procedures such as administering uterotonic drugs (58 % v. 100 %), and to require assessment of postpartum status in the electronic health record (0 % v. 33 %). The majority (19/35; 54 %) of responding ED managers had not offered obstetric emergency training to staff in the last two years.
CONCLUSIONS
While obstetric emergencies are not uncommon in the Arkansas hospital EDs represented in this…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.